Keeping an Eye Out for Immunotherapy Toxicity: A Case of Unilateral Ptosis Caused by Ipilimumab/Nivolumab Therapy.
J Immunother Precis Oncol
; 7(2): 126-129, 2024 May.
Article
en En
| MEDLINE
| ID: mdl-38721405
ABSTRACT
Despite ocular adverse events from immune checkpoint inhibitors being uncommon, they are still important complications to be aware of. We present the case of metastatic melanoma on ipilimumab/nivolumab in a patient who developed immunotherapy complications with delayed diagnosis because the only presenting symptom was unilateral ptosis. We reviewed the literature for relevant and important ocular and neurological complications of immune checkpoint inhibitors.
Texto completo:
1
Base de datos:
MEDLINE
Idioma:
En
Revista:
J Immunother Precis Oncol
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos